Drug treats hepatitis C by targeting body's RNA

03/27/2013 | Science News

A new compound drug could be effective in treating hepatitis C by attacking RNA that allows the virus to gain traction in a patient's body. The drug, miravirsen, targets the body's microRNA-122, preventing viral replication, according to findings published in the New England Journal of Medicine. The treatment could potentially also treat other serious diseases, including cancer. "This is really a revolution in science and it's now beginning to be translated into advances that control disease," said Phillip Sharp, an MIT molecular biologist who won a 1993 Nobel Prize for work on RNA.

View Full Article in:

Science News

Published in Briefs:

SmartBrief Job Listings for Education

Job Title Company Location
Partner - Strategy, Systems and Policy
TNTP
Nationwide, SL_Nationwide
Professional Development Manager (West Coast residence preferred)
Rowland Reading Foundation
Nationwide, SL_Nationwide
Deputy Director for Curriculum, Instruction & Assessment
Department of Defense Education Activity (DoDEA)
Wiesbaden
School District of Philadelphia - Director, Observation and Feedback Coaches Program
School District of Philadelphia
Philadelphia, PA
SENIOR PROJECT ASSOCIATE FOR PROGRAMMING FOR ENGLISH LANGUAGE LEARNERS
Center for Collaborative Education
Boston, MA